Combined growth hormone and insulin-like growth factor-1 rescues growth retardation in glucocorticoid-treated mdxmice but does not prevent osteopenia
| العنوان: | Combined growth hormone and insulin-like growth factor-1 rescues growth retardation in glucocorticoid-treated mdxmice but does not prevent osteopenia |
|---|---|
| المؤلفون: | Claire L Wood, Rob van ‘t Hof, Scott Dillon, Volker Straub, Sze C Wong, S Faisal Ahmed, Colin Farquharson |
| المصدر: | Wood, C L, Van't Hof, R, Dillon, S, Straub, V, Wong, S C, Ahmed, S F & Farquharson, C 2022, ' Combined growth hormone and insulin-like growth factor 1 rescues growth retardation in glucocorticoid-treated mdx mice but does not prevent osteopenia ', Journal of Endocrinology, vol. 253, no. 2, pp. 63-74 . https://doi.org/10.1530/JOE-21-0388Test |
| بيانات النشر: | Bioscientifica, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | bone-muscle interactions, bone QCT/micro CT, Human Growth Hormone, genetic animal models, Endocrinology, Diabetes and Metabolism, X-Ray Microtomography, Mice, Inbred C57BL, Muscular Dystrophy, Duchenne, Bone Diseases, Metabolic, Mice, Endocrinology, Growth Hormone, Mice, Inbred mdx, GH/IGF-1, Animals, Humans, Insulin-Like Growth Factor I, Glucocorticoids, Growth Disorders |
| الوصف: | Short stature and osteoporosis are common in Duchenne muscular dystrophy (DMD) and its pathophysiology may include an abnormality of the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis, which is further exacerbated by long-term glucocorticoid (GC) treatment. Hence, an agent that has anabolic properties and may improve linear growth would be beneficial in this setting and therefore requires further exploration. A 5-week-old x-linked muscular dystrophy (mdx) mice were used as a model of DMD. They were treated with prednisolone ± GH + IGF-1 for 4 weeks and then compared to control mdx mice to allow the study of both growth and skeletal structure. GC reduced cortical bone area, bone fraction, tissue area and volume and cortical bone volume, as assessed by micro computed tomography (CT) In addition, GC caused somatic and skeletal growth retardation but improved grip strength. The addition of GH + IGF-1 therapy rescued the somatic growth retardation and induced additional improvements in grip strength (16.9% increase, P < 0.05 compared to control). There was no improvement in bone microarchitecture (assessed by micro-CT and static histomorphometry) or biomechanical properties (assessed by three-point bending). Serum bone turnover markers (Serum procollagen 1 intact N-terminal propeptide (P1NP), alpha C-terminal telopeptide (αCTX)) also remained unaffected. Further work is needed to maximise these gains before proceeding to clinical trials in boys with DMD. |
| وصف الملف: | application/pdf |
| تدمد: | 1479-6805 0022-0795 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a77d97c1dcf86a6deeeef8c8569be0c0Test https://doi.org/10.1530/joe-21-0388Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a77d97c1dcf86a6deeeef8c8569be0c0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14796805 00220795 |
|---|